Marken adds Russian depot center for clinical trial materials storage

By Zachary Brennan

- Last updated on GMT

Marken expands to Russia to meet client demand
Marken expands to Russia to meet client demand

Related tags: Russia

Marken on Wednesday announced its pharma depot network is expanding to Russia to meet the growing needs of clients looking to store materials for clinical trials there and in Eastern Europe.

The Russia depot will be located within an existing GxP-compliant storage facility near the airport in Moscow. The facility will be operated by local staff trained on Marken’s global procedures and the company’s inventory system, which provides round-the-clock access and monitoring of clients’ global supplies and distribution status.

CEO Wes Wheeler told Outsourcing-Pharma.com, “We’ve been in Russia for 10 years and we collect and service from 80 cities there, with an established transport network and existing clients​.”

The transportation network is key for companies looking to send clinical trial supplies outbound to trial sites in Eastern Europe, Wheeler said.

He added that he will soon appoint a general manager for the company’s Eastern European operations as the company looks to make a bigger, more formal push into the region.

We intend to form a legal entity in Russia and Ukraine​,” he said.

Regional partnership

Marken is also forming a partnership with IMP Logistics, which offers similar warehousing and logistical support for trials in Russia, Belarus and Ukraine. “Russia is still in the top five or six countries to conduct clinical trials, so client demand is expected to remain high.”

The Russia site will be integrated into a network of depots including ones that already are in China, Singapore, Argentina, Mexico, Germany, and the US.

Wheeler added that Marken is “going live with at least two or three more depots by the end of the year​.”

The depots are designed for all clinical materials, and are suited for temperature-controlled, time sensitive products which are emerging in a number of pharma company pipelines.

Related news

Show more

Related products

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Local lab Data Management

Local lab Data Management

Q² Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars